MedTrace Logo

Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients

NCT03887065 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-05-07

No results posted yet for this study

Summary

This is a Phase 0/1 study of MS patients to determine the safety and potential efficacy of a novel, small human peptide designated as JM-4. The study will involve treatment for 5-7 days with JM-4 to determine the effects of Gadolinium(+) lesion number and volume in the brains of patients.

Conditions

Interventions

DRUG

JM-4

Novel small human peptide derived from erythropoietin

Sponsors & Collaborators

  • Cook, Stuart, MD

    lead OTHER

Principal Investigators

  • Stuart Cook, MD · VA Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-15
Primary Completion
2019-12-15
Completion
2020-03-15
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03887065 on ClinicalTrials.gov